Cardiogenic shock: What’s new?
https://doi.org/10.29001/2073-8552-2021-36-4-45-51
Abstract
Cardiogenic shock mortality did not decrease over the past decade despite the large number of studies focusing on the problem and the achieved success in the treatment of myocardial infarction. This provides rationale for search for new approaches to studying the problem in order to identify new opportunities to change the current situation. The article analyzes the experience of completed clinical trials and characterizes prospective studies on the treatment of cardiogenic shock.
About the Authors
O. O. Panteleev
Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
Russian Federation
Russian Federation
Junior Research Scientist, Department of Emergency Cardiology; Assistant Professor, Department of Cardiology, Continuous Medical Education Faculty, Siberian State Medical University
111a, Kievskaya str., Tomsk, 634012, Russian Federation
V. V. Ryabov
Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
Russian Federation
Russian Federation
Dr. Sci. (Med.), Head of Department of Emergency Cardiology; Associate Professor, Department of Cardiology, Continuous Medical Education Faculty,
Siberian State Medical University; Leading Research Scientist, Laboratory of
Translational Cellular and Molecular Biomedicine, National Research Tomsk
State University
111a, Kievskaya str., Tomsk, 634012, Russian Federation
References
1. Global, regional, and national age-sex specifi c all-cause and cause-specifi c mortality for 240 causes of death, 1990–2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–171. DOI: 10.1016/S0140-6736(14)61682-2.
2. Pole D.J., Thompson P.L., Woodings T.L., McCall M.G., Reader R. Acute myocardial infarction: Оne year follow-up of 1138 cases from the Perth Community Coronary Register. Aust. N. Z. J. Med. 1976;6(5):437–440. DOI: 10.1111/j.1445-5994.1976.tb03031.x.
3. Johansson S., Rosengren A., Young K., Jennings E. Mortality and morbidity trends after the fi rst year in survivors of acute myocardial infarction: A systematic review. BMC Cardiovasc. Disord. 2017;17(1):53. DOI: 10.1186/s12872-017-0482-9.
4. Grigoryev E.V., Bautin A.E., Kirov M.Yu., Shukevich D.L., Kornelyuk R.A. Cardiogenic shock associated with acute coronary syndrome: The current state of the problem of diagnostics and intensive care. Article. Annals of Critical Care. 2020;2:73–85 (In Russ.). DOI: 10.21320/1818-474X-2020-2-73-85.
5. Holmes D.R. Jr., Bates E.R., Kleiman N.S., Sadowski Z., Horgan J.H., Morris D.C. et al. Contemporary reperfusion therapy for cardiogenic shock: The GUSTO-I trial experience. J. Am. Coll. Cardiol. 1995;26(3):668–674. DOI: 10.1016/0735-1097(95)00215-p.
6. Karnash S.L., Granger C.B., White H.D., Woodlief L.H., Topol E.J., Califf R.M. Treating menstruating women with thrombolytic therapy: Insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO-I) trial. J. Am. Coll. Cardiol. 1995;26(7):1651–1656. DOI: 10.1016/0735-1097(95)00386-x.
7. Hochman J.S., Sleeper L.A., Webb J.G., Sanborn T.A., White H.D., Talley J.D. et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N. Engl. J. Med. 1999;341(9):625–634. DOI: 10.1056/NEJM199908263410901.
8. Vetrovec G.W., Anderson M., Schreiber T., Popma J., Lombardi W., Maini B. et al. The cVAD registry for percutaneous temporary hemodynamic support: A prospective registry of Impella mechanical circulatory support use in high-risk PCI, cardiogenic shock, and decompensated heart failure. Am. Heart J. 2018;199:115–121. DOI: 10.1016/j.ahj.2017.09.007.
9. Shah A.H., Puri R., Kalra A. Management of cardiogenic shock complicating acute myocardial infarction: A review. Clin. Cardiol. 2019;42(4):484–493. DOI: 10.1002/clc.23168.
10. Menon V., Fincke R. Cardiogenic shock: A summary of the randomized SHOCK trial. Congest. Heart Fail. 2003;9(1):35–39. DOI: 10.1111/j.1751-7133.2003.tb00020.x.
11. Oeing C.U., Tschöpe C., Pieske B. [The new ESC Guidelines for acute and chronic heart failure 2016]. Herz. 2016;41(8):655–663 (In Germ.). DOI: 10.1007/s00059-016-4496-3.
12. Ibanez B., James S., Agewall S., Antunes M.J., Bucciarelli-Ducci C., Bueno H. et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 2018;39(2):119–177. DOI: 10.1093/eurheartj/ehx393.
13. Collet J.P., Thiele H., Barbato E., Barthélémy O., Bauersachs J., Bhatt D.L. et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J. 2021;42(14):1289–1367. DOI: 10.1093/eurheartj/ehaa575.
14. Baran D.A., Grines C.L., Bailey S., Burkhoff D., Hall S.A., Henry T.D. et al. SCAI clinical expert consensus statement on the classification of cardiogenic shock: This document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019. Catheter Cardiovasc. Interv. 2019;94(1):29–37. DOI: 10.1002/ccd.28329.
15. Jentzer J.C., van Diepen S., Barsness G.W., Henry T.D., Menon V., Rihal C.S. et al. Cardiogenic shock classification to predict mortality in the cardiac intensive care unit. J. Am. Coll. Cardiol. 2019;74(17):2117–2128. DOI: 10.1016/j.jacc.2019.07.077.
16. Fincke R., Hochman J.S., Lowe A.M., Menon V., Slater J.N., Webb J.G. et al. Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: A report from the SHOCK trial registry. J. Am. Coll. Cardiol. 2004;44(2):340–8. DOI: 10.1016/j.jacc.2004.03.060.
17. Parissis H., Graham V., Lampridis S., Lau M., Hooks G., Mhandu P.C. IABP: History-evolution-pathophysiology-indications: What we need to know. J. Cardiothorac. Surg. 2016;11(1):122. DOI: 10.1186/s13019-016-0513-0.
18. Wong A.S.K., Sin S.W.C. Short-term mechanical circulatory support (intra-aortic balloon pump, Impella, extracorporeal membrane oxygenation, TandemHeart): a review. Ann. Transl. Med. 2020 Jul;8(13):829. DOI: 10.21037/atm-20-2171.
19. Den Uil C.A., Daemen J., Lenzen M.J., Maugenest A.M., Joziasse L., van Geuns R.J. et al. Pulsatile iVAC 2L circulatory support in high-risk percutaneous coronary intervention. EuroIntervention. 2017;12(14):1689–1696. DOI: 10.4244/EIJ-D-16-00371.
20. Napp L.C., Kühn C., Bauersachs J. ECMO in cardiac arrest and cardiogenic shock. Herz. 2017;42(1):27–44. DOI: 10.1007/s00059-016-4523-4.
21. Timóteo A.T., Nogueira M.A., Rosa S.A., Belo A., Ferreira R.C.; ProACS Investigators. Role of intra-aortic balloon pump counterpulsation in the treatment of acute myocardial infarction complicated by cardiogenic shock: Evidence from the Portuguese nationwide registry. Eur. Heart J. Acute Cardiovasc. Care. 2016;5(7):23–31. DOI: 10.1177/2048872615606600.
22. Ouweneel D.M., Eriksen E., Sjauw K.D., van Dongen I.M., Hirsch A., Packer E.J. et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. J. Am. Coll. Cardiol. 2017;69(3):278–287. DOI: 10.1016/j.jacc.2016.10.022.
23. Basir M.B., Schreiber T.L., Grines C.L., Dixon S.R., Moses J.W., Maini B.S. et al. Effect of early initiation of mechanical circulatory support on survival in cardiogenic shock. Am. J. Cardiol. 2017;119(6):845–851. DOI: 10.1016/j.amjcard.2016.11.037.
24. Stretch R., Sauer C.M., Yuh D.D., Bonde P. National trends in the utilization of short-term mechanical circulatory support: incidence, outcomes, and cost analysis. J. Am. Coll. Cardiol. 2014;64(14):1407–1415. DOI: 10.1016/j.jacc.2014.07.958.
Review
For citations:
Panteleev O.O., Ryabov V.V. Cardiogenic shock: What’s new? Siberian Journal of Clinical and Experimental Medicine. 2021;36(4):45-51. (In Russ.) https://doi.org/10.29001/2073-8552-2021-36-4-45-51
Views:
936
.png)
Email this article 